Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    00486460
Show Display Options
Rank Status Study
1 Unknown  Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Advance or Inoperable Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine;   Drug: Curcumin;   Drug: Celebrex

Indicates status has not been verified in more than two years